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knowledge, clinical adoption and discussion of applied and translational
genomics worldwide” [1]. But, it is still unclear what is meant by the
term translational genomics. There are varying deﬁnitions of translational
research [2] that have been applied to genomic medicine [3] and other
areas (e.g., cancer survivorship research [4]).
Here, we brieﬂy describe our view deﬁnition of translational re-
search in genomics as spanning the whole spectrum of scientiﬁc activi-
ties going beyond the traditional “bench to bedside”model [1] to amore
expanded continuum that includes improvement in healthcare and
disease prevention [5]. We have previously described this framework
(described as T0-T4 research) [6,7]. Currently, there is a great amount
of genomic discovery research occurring that includes new genomic
variants, biomarkers and other basic science discoveries (T0). Beyond
the initial discovery, there are 4 overlapping phases of translational
genomic research (Fig. 1): T1 research,which bridges discovery to candi-
date health applications, or “bench to beside”. T1 research encompasses
the development of new diagnostic tests or interventions in the clinical
setting but in a limited fashion. An example of T1 research would be
evaluating gene–environment interactions or evaluating the function
of genomic variants. T2 research evaluates the clinical utility of candi-
date genomic applications in clinical practice. For example, this type
of research would include whether a genomic application performs
better than the standard of care in improving health outcomes or devel-
oping evidence from the clinical setting to informed evidence-based
guidelines. T3 research includes studies that assess implementation
and integration of genomics into routine clinical practice. T3 research
would include, for example, the evaluation of implementing genomic
applications in community-based centers. T4 research evaluates popu-
lation health impact of genomic medicine. An example of T4 research
would be performing nationwide surveillance to evaluate how the
implementation of a particular genomic test has affected population
health.
Currently, there is very little genomics research conducted and pub-
lished in T2-T4 research. For example, the NCI's Cancer Genomics andhttp://dx.doi.org/10.1016/j.atg.2014.09.006
2212-0661/© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NEpidemiology Navigator (CGEN http://epi.grants.cancer.gov/cgen), an
online freely accessible tool about resources and publications for cancer
genomics and epidemiology research, indicates that there are over
22,500 cancer-related genomic epidemiology (HumanGenomic Epidemi-
ology (HuGE)) publications. From the same database we see that there
are currently 344 genomic applications that have been proposed for
cancer care and prevention since 2009. In addition, there are only 70
evidence-based recommendations that address cancer-based genomic
test. Only 26 are recommended for use of the application in a health
care setting byprofessional groups or guideline developers (tier 1 applica-
tions). The vast majority have insufﬁcient evidence base or negative
recommendation for use. Additionally, groups such as the Ofﬁce of Public
Health Genomics at the Centers for Disease Control and Prevention have
made an attempt to categorize genomic applications in terms of the
level of synthesized evidence for their use in a clinical setting [8] to help
guide researchers, policy makers and practitioners. This is the same
trend that we see over and over again in the ﬁeld of genomics. There
are thousands of studies that show promising genomic discoveries that
lead to promising interventions. However, only a few of these interven-
tions “stick” and make an impact on healthcare. Schully et al. [7,9] as
well as Clyne [10] found that less than 2% of cancer genomics research
funded by the National Cancer Institute and less than 0.5% of published
cancer genomics research is T2 andbeyond. Additionally, a recent analysis
of theNational Heart Lung and Blood Institute's genomics portfolio shows
a similar trend [10]. Implementation of genomic applications that lack an
evidence base can have high costs in terms of adverse health outcomes
and increased health care costs.
Since it is unlikely that randomized clinical trials (RCTs) will be
performed on every promising genomic application, researchers must
strive to gain an evidence base for these applications by conducting
appropriate observational studies [11] and comparative effectiveness
research [12].
Once a promising intervention is identiﬁed in genomics, critical
research is needed in order to determine if the application should be
recommended for routine use in a health care setting. Behavioral andC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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zation and patient communication. Comparative effectiveness research
(CER) also is needed to determine the clinical validity and utility of the
applications, in comparison with existing practice. Additionally, health
services and implementation research can track integration of tests in
practice and measure disparities in access [13]. Additionally, multi-
level research should also be performed to evaluate how an individual's
external environment (family dynamics, neighborhood factors, state
and federal policies, etc.) affects the overall outcomes of the genomic
application [14].
If we continue to perform T0-T1 research without also addressing be-
havioral, CER, implementation, utilization, surveillance, and multi-level
research, the promise of genomic medicine for improving health and
preventing disease will not be fulﬁlled. All phases of translation research,
especially T2+ research are integral to making a population health
impact.
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